Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, announced a CNY 180 million Series B financing.